BGM Group (BGM) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed BGM Group (BGM) over the past year, gaining 23.7% versus a loss of 96.3%. Over five years, NERV leads with a -70.6% price change compared with -98.2% for BGM. Minerva Neurosciences is the larger company by market cap ($151.8 million vs $143.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | NERV |
|---|---|---|
| Share price | $10.75 | $3.18 |
| Market cap | $143.56M | $151.84M |
| 1-day change | +10.94% | -1.24% |
| YTD return | -90.29% | -20.90% |
| 1-year return | -96.31% | +23.74% |
| 5-year return | -98.19% | -70.56% |
| EPS (TTM) | $-4.80 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $12.46 |
| 52-week low | $6.45 | $2.24 |
| Distance from 52-week high | -96.45% | -74.48% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +224.84% |
| Average volume | 6.11K | 183.63K |
| Shares outstanding | 12.69M | 47.75M |
| Employees | — | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed BGM by 120.0 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
BGM vs NERV FAQ
Which is bigger, BGM Group or Minerva Neurosciences?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $151.84M compared with $143.56M for BGM Group (BGM).
Which stock has performed better over the past year, BGM or NERV?
NERV returned +23.74% over the past 12 months, compared with -96.31% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.